A446440 Stock Overview
A biopharmaceutical research company, develops cell and antibody treatments for hair restoration medical needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Epibiotech Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩12,290.00 |
| 52 Week High | ₩13,570.00 |
| 52 Week Low | ₩8,110.00 |
| Beta | 0 |
| 11 Month Change | 17.05% |
| 3 Month Change | 25.54% |
| 1 Year Change | 11.93% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -51.80% |
Recent News & Updates
Recent updates
Shareholder Returns
| A446440 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 6.9% | -5.8% | -2.8% |
| 1Y | 11.9% | 28.2% | -3.4% |
Return vs Industry: A446440 underperformed the KR Biotechs industry which returned 28.2% over the past year.
Return vs Market: A446440 exceeded the KR Market which returned -3.4% over the past year.
Price Volatility
| A446440 volatility | |
|---|---|
| A446440 Average Weekly Movement | 7.2% |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in KR Market | 11.5% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A446440 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A446440's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | n/a | n/a | epibiotech.com |
Epibiotech Co., Ltd., a biopharmaceutical research company, develops cell and antibody treatments for hair restoration medical needs. The company was formerly known as Stemore Co., Ltd. and changed its name to Epibiotech Co., Ltd.
Epibiotech Co., Ltd. Fundamentals Summary
| A446440 fundamental statistics | |
|---|---|
| Market cap | ₩28.24b |
| Earnings (TTM) | ₩0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs A446440 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A446440 income statement (TTM) | |
|---|---|
| Revenue | ₩0 |
| Cost of Revenue | ₩0 |
| Gross Profit | ₩0 |
| Other Expenses | ₩0 |
| Earnings | ₩0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A446440 perform over the long term?
See historical performance and comparison